TREATMENT
Review: immediate antiplatelet therapy after acute ischaemic stroke reduces death or dependency and risk of recurrent stroke
| The first 150 words of the full text of this article appear below. |
P A Sandercock
Dr P A Sandercock, University of Edinburgh, Edinburgh, UK; peter.sandercock@ed.ac.uk
What is the efficacy and safety of immediate antiplatelet therapy after acute ischaemic stroke?
Included studies compared antiplatelet therapy, including aspirin, abciximab, heparin, and ticlopidine (started within 14 d of stroke) with placebo or no treatment in patients with acute ischaemic stroke. Studies of antiplatelet therapy after primary intracerebral or subarachnoid haemorrhage, or drugs with multiple modes of action (eg, piracetam, prostacyclin, and oxpentifylline) were excluded. Outcomes included death or dependence on others for activities of daily living 1 month after stroke, all-cause mortality, deep venous thrombosis, pulmonary embolism, recurrent stroke, and intracranial and extracranial haemorrhage.
Medline, EMBASE/Excerpta Medica, Cochrane Stroke Group Trials Register, Cochrane Library (Issue 2, 2007), Antiplatelet Trialists Collaboration, MedStrategy, and reference lists were searched, and drug companies were contacted for randomised controlled trials (RCTs). 12 RCTs (n = 43 041, mean age range
Hamilton Health Sciences—General Site, Hamilton, Ontario, Canada
Register for free content
The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.
